Clinical trial
The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
NCT02121470 is registered in ClinicalTrials.gov with BioPorto Diagnostics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US
- Lead sponsor
- BioPorto Diagnostics
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 28, 2014
- Completion date
- June 30, 2015
- Enrollment
- 252 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.